Project Grant R21CA297404
Award Date 8/1/25
Completion Date 7/31/27
Dollars Obligated $422K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
- The University of Texas MD Anderson Cancer Center was awarded a $616,715 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) on August 11, 2025. The grant supports the development of a novel "Microbial-Inspired Immune-Stimulating Antibody-Toxin Conjugate (ATC) for Cancer Immunotherapy". The project aims to engineer an ATC that combines an anti-CD47 antibody with the Listeria monocytogenes toxin LLO, linked via a cleavable linker. This ATC is...
- This $421,685 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research conducted by the University of California, San Francisco (UCSF) to investigate the "reactive" immune system in tumors and the tumor microenvironment. The study aims to discover discrete immune cell niches within the tumor that can enhance the effectiveness of cancer immunotherapies. Using innovative spatial transcriptomics, genetic tools, and cellular...
- This $147,486 Project Grant was awarded by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to Baylor College of Medicine on December 1, 2025, with a completion date of April 20, 2027. The grant supports a novel immune tolerization strategy called RECON to investigate the trade-offs between oncogene pathogenicity and immunogenicity. The key objective is to uncouple an oncogene's pathogenic potential from its immunogenic properties, enabling the dissection of genetic and...
- This $421,685 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Texas MD Anderson Cancer Center supports research to investigate how the LIFR-LCN2 pathway in liver cancer restricts the cytotoxic function of CD8+ T cells, leading to immune evasion and resistance to immunotherapy. The central hypothesis is that loss of LIFR upregulates LCN2 in liver cancer, thereby suppressing the abundance and cytotoxic function of CD8+...
- This $2,638,738.00 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to understand how aging increases the metastatic competence of the omentum, a fatty tissue that is a common site of metastasis in ovarian cancer. The research aims to identify the mechanisms by which aging increases the accumulation of immunosuppressive innate-like B cells in the omentum, and to develop strategies to decrease the metastatic competence of the omentum...
- The National Cancer Institute (NCI) awarded a $602,881 Project Grant under CFDA 93.395, the Cancer Treatment Research program, to Duke University. The grant supports research to develop novel immunotherapies using engineered IgG antibodies that can penetrate tumor cells and neutralize oncogenic mutations, such as KRAS. The research aims to translate these tumor cell-penetrating antibodies into the clinic, overcoming challenges associated with the low yield and half-life of previous recombinant...
- This $112,230 federal Project Grant awarded by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to The University of Texas M.D. Anderson Cancer Center will support research to evaluate the potential of Type 1 conventional dendritic cell (CDC1) vaccination, alone and in combination with anti-CTLA4 immune checkpoint blockade, to induce antigen spread and generate diverse, effective CD8+ T cell responses against melanoma tumors. The project aims to study the ability of CDC1...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $216,682 to The Trustees of the University of Pennsylvania to develop "tumor-site activated T cell redirecting autoantibodies" - a novel cancer immunotherapy approach. The award period runs from March 1, 2025 to February 28, 2027. The project aims to leverage a patient's own anti-tumor autoantibodies to enhance the immune system's ability to target and clear cancer cells,...
- The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $1,847,485 Project Grant to The University of Texas MD Anderson Cancer Center to advance next-generation CAR-NK (chimeric antigen receptor-modified natural killer) cell therapies targeting CD5-positive T-cell malignancies. The award, effective September 19, 2025 through August 31, 2029, will support the development and clinical testing of an engineered CAR-NK cell product expressing an anti-CD5 scFv, IL-15 for...
- The National Cancer Institute (NCI) awarded a $226,504 Project Grant (CFDA 93.396 - Cancer Biology Research) to the Rector & Visitors of the University of Virginia (UVA) to elucidate the role of B/T cell-enriched immune aggregates in immune surveillance against triple-negative breast cancer (TNBC). The project aims to study how these novel immune aggregates form and function to control pre-malignant progression of TNBC, which could inform future strategies to enhance immune surveillance...